ArticleFrontiers in cardiovascular medicine2025
Characterizing hub biomarkers for metabolic-induced endothelial dysfunction and unveiling their regulatory roles in EndMT through RNA sequencing and machine learning approaches.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic disorder and endothelial dysfunction (ED) are key events in the development and pathophysiology of atherosclerosis and are associated with an elevated risk of Cardiovascular disease (CVD). The pathophysiology remains incompletely understood. Methods: Leftover serum samples were collected and stored at -20 °C until study. Serum specimens were mixed to obtain pooled high glucose serum (GLU group) (11.97 ± 2.09 mmol/L); pooled elevated low-density lipoprotein serum (LDL group) [3.465 (3.3275, 3.6425 mmol/L)]; pooled high triglycerides serum (1.15 ± 0.35 mmol/L) (TG group); Subsequently, Human umbilical vein endothelial cells (HUVECs) were exposed to culture media supplemented with these pooled serum or control serum for 72 h. Whole transcriptome sequencing was performed to characterize gene expression profiles and data were analyzed using GSEA, GO, KEGG. qPCR was used to validate the gene expression. Results: A total of 306 mRNAs and 523 lncRNAs were identified as differentially expressed in the GLU group, 335 mRNAs and 471 lncRNAs in the LDL group, and 364 mRNAs and 562 lncRNAs in the TG group, compared to the control group. These genes are primarily involved in inflammation, lipid metabolism, and EndMT pathways. By integrating differentially expressed mRNA and curated EndMT-related gene sets from the KEGG, GO, and dbEMT2.0 databases, we identified 52 differentially expressed genes associated with EndMT under metabolic stress conditions. Utilizing machine learning techniques, we established an EndMT-associated gene diagnostic signature comprising CD36, ISG15, HSPB2, and IRS2 for the diagnosis of AS, which achieved an AUC of 0.997. The model was subsequently validated across three independent external cohorts (GSE43292, GSE28829, GSE163154), in which it consistently demonstrated strong diagnostic performance, with AUC values of 0.958, 0.808, and 0.884, respectively. The ceRNA networks associated with EndMT are constructed and related lncRNAs including LINC002381, VIM-AS1, and ELF-AS1 were significantly upregulated in peripheral blood samples. Conclusions: This study identified novel biomarkers for ED. These findings may provide both a potential biomarker and therapeutic target for the prevention and treatment of atherosclerosis and CAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.